Pancreatic Cancer Market size was valued at US$ 6.04 Bn. in 2022 and is expected to grow at a CAGR of 7.3% through 2023 to 2029. Radiation Therapy segment leads the Global Pancreatic Cancer Market by 2029.
Pancreatic Cancer Market Overview:The Global Pancreatic Cancer market was valued at US $6.04 Bn. in 2022, and it is expected to reach US $9.89 Bn. by 2029 with a CAGR of 7.3% during the forecast period. Pancreatic cancer is a major reason of cancer-associated mortality, with very poor whole diagnosis and prognosis that has remained virtually unchanged for many years. Hence, the global pancreatic cancer market has the huge opportunities to improve the treatment and diagnosis. To know about the Research Methodology :- Request Free Sample Report
Pancreatic Cancer Market Dynamics:The survival of 80% of the patients are extended by the emergence of new drug therapies and new drug combinations. Obesity and low physical activities are associated to pancreatic cancer. Some nutritional and dietary factors, such as high intake of fats, low intake of vegetables, and consumption of red and progressed meat are the causes behind the rising population suffering from pancreatic cancer disease and dominating the global market by new technological advances in surgical therapies, chemotherapies and radiation therapies. Invention of some laboratory and imaging tests supporting the diagnosis of pancreatic cancer are boosting the global market by 2029. Increasing management skills of healthcare persons support in surgery, chemotherapy, and radiotherapy to save the lives of the individuals. Pancreatic ductal adenocarcinoma accounts for approximately 90% of pancreatic cancers (PDAC). Familial risk related to susceptibility gene mutations, chronic pancreatitis, pancreatic cysts, and diabetes mellitus are all risk factors for pancreatic cancer. Smoking, alcohol abuse, obesity or metabolic syndrome, ageing, and occupational exposure are all risk factors. 4,7 Around 80% of pancreatic cancer patients have advanced disease or distant metastases, and there are no viable therapeutic alternatives. 8 Even patients who are eligible for resection at an early stage have a 5-year survival rate of 31%. Advances in next-generation genome sequencing (NGS) have brought new enthusiasm to the field by supporting the identification of molecular changes that govern pancreatic cancer development. Limited options of therapeutic and low progress in the development of drug are the major restrains that hamper the growth of the pancreatic cancer market. However, diagnosis and therapy of pancreatic cancer stay a difficult challenge in the forecast period.
Pancreatic Cancer Market Segment Analysis:The Global Pancreatic Cancer Market is segmented by Treatment, and Test. Based on the Treatment, the market is segmented into Surgery, Chemotherapy, Radiation Therapy, and Targeted Therapy. Radiation Therapy is expected to hold the largest market shares of xx% by 2029. The key benefit of radiation therapy is that it supports to control the growth of the cancers. For a small number of people with uncertain resectable cancer and nearby advanced pancreatic cancer, radiotherapy may help to make surgery possible. Each treatment session will take about 30 minutes and we will not usually need to stay in hospital. We are able to carry on with our daily life, like going to work, if we feel up to it. Radiation therapy surgery process is the only treatment that has been shown to recover the 5-year survival rate to 20-25%. From the total number of patients across the world, only 10% of PC patients are diagnosed at an initial stage, hence there are vast opportunities for radiation therapy to cure the patients detected with pancreatic cancer. New technological changes in radiation therapy give the significant outcomes with less harm. According to world health organization (WHO), radiation therapy is ideal treatment for the 50% of pancreatic cancer cases in the globe. Based on the Test, the market is segmented into Imaging Test, Biopsy, and Blood Test. Biopsy segment is expected to grow rapidly at a CAGR of xx% during the forecast period 2023-2029. A biopsy is the main technique for doctors to diagnose pancreatic cancer. Pancreatic cancer is asymptomatic at an initial stage; hence biopsy is the best solution for the diagnosis of cancer at initial stage. Latest inventions in image guided biopsy support the professionals to study the ploidy and growing rate of cancer cells. To surge the complete survival of patients, the biopsy segment is expected to hold the largest market share of xx% in the global market. Innovative method of liquid biopsy is the lucrative opportunity for the global market.
Regional Insights:North America dominates the Global Pancreatic Cancer market during the forecast period 2023-2029. North America is expected to hold the largest market shares of xx% by 2029. Pancreatic cancer is the 4th leading cause of cancer-related death in the North America region, with rising incidence. The mortality rate of pancreatic cancer is increasing rapidly, and it is expected to be the most common of all malignant tumours by 2030. Patients from North America travel only to one of the Cancer Treatment Centres of America (CTCA) hospitals, accounting for about 70% of all CTCA patients. Due to the availability of skilled physicians and significant effort, various innovative procedures for early detection and treatment of all cancer kinds, particularly abdominal and pancreatic cancer, have been developed. To combat cancer, governments from North American countries provide advanced technologies and instruments to hospitals and cancer centres. Supportive care services have also been developed to help lessen side effects and increase quality of life. The objective of the report is to present a comprehensive analysis of the Global Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Global Market dynamic, structure by analyzing the market segments and project the Global Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Market make the report investor’s guide.
Pancreatic Cancer Market Scope:Inquire before buying
Pancreatic Cancer Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 6.04 Bn. Forecast Period 2023 to 2029 CAGR: 7.3% Market Size in 2029: US $ 9.89 Bn. Segments Covered: by Treatment Surgery Chemotherapy Radiation Therapy Targeted Therapy by Test Imaging Test Biopsy Blood Test
Pancreatic Cancer Market, by RegionNorth America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (razil, Argentina Rest of South America)
Key Players:1. Pharmacyte Biotech Inc. 2. OncoGenex Pharmaceuticals Inc. 3. Oncolytics Biotech 4. Diffusion Pharmaceuticals 5. Polaris Pharmaceuticals, Inc. 6. Sun BioPharma, Inc. 7. Midatech Pharma PLC 8. Eli Lilly and Company 9. Celgene Corporation 10. F. Hoffmann-La Roche AG 11. Amgen, Inc. 12. Novartis International AG 13. Clovis Oncology 14. Others Frequently Asked Questions: 1] What segments are covered in Global Pancreatic Cancer Market report? Ans. The segments covered in Global Pancreatic Cancer Market report are based on Treatment, and Test. 2] Which region is expected to hold the highest share in the Global Pancreatic Cancer Market? Ans. North America is expected to hold the highest share in the Global Pancreatic Cancer Market. 3] Who are the top key players in the Global Pancreatic Cancer Market? Ans. Pharmacyte Biotech Inc., OncoGenex Pharmaceuticals Inc., Oncolytics Biotech, Diffusion Pharmaceuticals, and Polaris Pharmaceuticals, Inc. are the top key players in the Global Pancreatic Cancer Market. 4] Which segment holds the largest market share in the Global Pancreatic Cancer market by 2029? Ans. Radiation Therapy treatment segment hold the largest market share in the Global Pancreatic Cancer market by 2029. 5] What is the market size of the Global Pancreatic Cancer market by 2029? Ans. The market size of the Global Pancreatic Cancer market is US $9.89 Bn. by 2029. 6] What was the market size of the Global Pancreatic Cancer market in 2022? Ans. The market size of the Global Pancreatic Cancer market was worth US $6.04 Bn. in 2022.
1. Global Pancreatic Cancer Market: Research Methodology 2. Global Pancreatic Cancer Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Pancreatic Cancer Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Pancreatic Cancer Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Pancreatic Cancer Market Segmentation 4.1 Global Pancreatic Cancer Market, by Treatment (2022-2029) • Surgery • Chemotherapy • Radiation Therapy • Targeted Therapy 4.2 Global Pancreatic Cancer Market, by Test (2022-2029) • Imaging Test • Biopsy • Blood Test 5. North America Pancreatic Cancer Market (2022-2029) 5.1 Global Pancreatic Cancer Market, by Treatment (2022-2029) • Surgery • Chemotherapy • Radiation Therapy • Targeted Therapy 5.2 Global Pancreatic Cancer Market, by Test (2022-2029) • Imaging Test • Biopsy • Blood Test 5.3 North America Pancreatic Cancer Market, by Country (2022-2029) • United States • Canada • Mexico 6. Asia Pacific Pancreatic Cancer Market (2022-2029) 6.1. Asia Pacific Pancreatic Cancer Market, by Treatment (2022-2029) 6.2. Asia Pacific Pancreatic Cancer Market, by Test (2022-2029) 6.3. Asia Pacific Pancreatic Cancer Market, by Country (2022-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Pancreatic Cancer Market (2022-2029) 7.1 Middle East and Africa Pancreatic Cancer Market, by Treatment (2022-2029) 7.2. Middle East and Africa Pancreatic Cancer Market, by Test (2022-2029) 7.3. Middle East and Africa Pancreatic Cancer Market, by Country (2022-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Pancreatic Cancer Market (2022-2029) 8.1. Latin America Pancreatic Cancer Market, by Treatment (2022-2029) 8.2. Latin America Pancreatic Cancer Market, by Test (2022-2029) 8.3. Latin America Pancreatic Cancer Market, by Country (2022-2029) • Brazil • Argentina • Rest Of Latin America 9. European Pancreatic Cancer Market (2022-2029) 9.1. European Pancreatic Cancer Market, by Treatment (2022-2029) 9.2. European Pancreatic Cancer Market, by Test (2022-2029) 9.3. European Pancreatic Cancer Market, by Country (2022-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1. Pharmacyte Biotech Inc. 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. OncoGenex Pharmaceuticals Inc. 10.3. Oncolytics Biotech 10.4. Diffusion Pharmaceuticals 10.5. Polaris Pharmaceuticals, Inc. 10.6. Sun BioPharma, Inc. 10.7. Midatech Pharma PLC 10.8. Eli Lilly and Company 10.9. Celgene Corporation 10.10. F. Hoffmann-La Roche AG 10.11. Amgen, Inc. 10.12. Novartis International AG 10.13. Clovis Oncology 10.14. Others